These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 29474999)

  • 1. Serum metabolomics study in a group of Parkinson's disease patients from northern India.
    Nagesh Babu G; Gupta M; Paliwal VK; Singh S; Chatterji T; Roy R
    Clin Chim Acta; 2018 May; 480():214-219. PubMed ID: 29474999
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical correlates of serum insulin-like growth factor-1 in patients with Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Numao A; Suzuki K; Miyamoto M; Miyamoto T; Hirata K
    Parkinsonism Relat Disord; 2014 Feb; 20(2):212-6. PubMed ID: 24280021
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Subregional patterns of preferential striatal dopamine transporter loss differ in Parkinson disease, progressive supranuclear palsy, and multiple-system atrophy.
    Oh M; Kim JS; Kim JY; Shin KH; Park SH; Kim HO; Moon DH; Oh SJ; Chung SJ; Lee CS
    J Nucl Med; 2012 Mar; 53(3):399-406. PubMed ID: 22323779
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Serum uric acid levels in Parkinson's disease and related disorders.
    Sakuta H; Suzuki K; Miyamoto T; Miyamoto M; Numao A; Fujita H; Watanabe Y; Hirata K
    Brain Behav; 2017 Jan; 7(1):e00598. PubMed ID: 28127516
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topographical differences of brain iron deposition between progressive supranuclear palsy and parkinsonian variant multiple system atrophy.
    Han YH; Lee JH; Kang BM; Mun CW; Baik SK; Shin YI; Park KH
    J Neurol Sci; 2013 Feb; 325(1-2):29-35. PubMed ID: 23260321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Iodine 123-labeled meta-iodobenzylguanidine myocardial scintigraphy in the cases of idiopathic Parkinson's disease, multiple system atrophy, and progressive supranuclear palsy].
    Yoshita M; Hayashi M; Hirai S
    Rinsho Shinkeigaku; 1997 Jun; 37(6):476-82. PubMed ID: 9366173
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low serum uric acid levels in progressive supranuclear palsy.
    Oropesa-Ruiz JM; Huertas-Fernández I; Jesús S; Cáceres-Redondo MT; Vargas-Gonzalez L; Carrillo F; Carballo M; Gómez-Garre P; Mir P
    Mov Disord; 2016 Mar; 31(3):402-5. PubMed ID: 26686202
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum adiponectin levels between patients with Parkinson's disease and those with PSP.
    Kataoka H; Sugie K
    Neurol Sci; 2020 May; 41(5):1125-1131. PubMed ID: 31897945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diagnosis of Parkinson's disease and the level of oxidized DJ-1 protein.
    Yamagishi Y; Saigoh K; Saito Y; Ogawa I; Mitsui Y; Hamada Y; Samukawa M; Suzuki H; Kuwahara M; Hirano M; Noguchi N; Kusunoki S
    Neurosci Res; 2018 Mar; 128():58-62. PubMed ID: 28705587
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Apparent diffusion coefficient measurements of the middle cerebellar peduncle differentiate the Parkinson variant of MSA from Parkinson's disease and progressive supranuclear palsy.
    Nicoletti G; Lodi R; Condino F; Tonon C; Fera F; Malucelli E; Manners D; Zappia M; Morgante L; Barone P; Barbiroli B; Quattrone A
    Brain; 2006 Oct; 129(Pt 10):2679-87. PubMed ID: 16815875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Diffusion-weighted magnetic resonance imaging differentiates Parkinsonian variant of multiple-system atrophy from progressive supranuclear palsy.
    Paviour DC; Thornton JS; Lees AJ; Jäger HR
    Mov Disord; 2007 Jan; 22(1):68-74. PubMed ID: 17089396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Speech disorders reflect differing pathophysiology in Parkinson's disease, progressive supranuclear palsy and multiple system atrophy.
    Rusz J; Bonnet C; Klempíř J; Tykalová T; Baborová E; Novotný M; Rulseh A; Růžička E
    J Neurol; 2015; 262(4):992-1001. PubMed ID: 25683763
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A comparison of changes in proteasomal subunit expression in the substantia nigra in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Bukhatwa S; Zeng BY; Rose S; Jenner P
    Brain Res; 2010 Apr; 1326():174-83. PubMed ID: 20176003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nigral glutathione deficiency is not specific for idiopathic Parkinson's disease.
    Fitzmaurice PS; Ang L; Guttman M; Rajput AH; Furukawa Y; Kish SJ
    Mov Disord; 2003 Sep; 18(9):969-76. PubMed ID: 14502663
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of the dopaminergic degeneration in Parkinson's disease with [123I] beta-CIT and SPECT. Correlation with clinical findings and comparison with multiple system atrophy and progressive supranuclear palsy.
    Brücke T; Asenbaum S; Pirker W; Djamshidian S; Wenger S; Wöber C; Müller C; Podreka I
    J Neural Transm Suppl; 1997; 50():9-24. PubMed ID: 9120429
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patterns of Eye Movement Impairment Correlate with Regional Brain Atrophy in Neurodegenerative Parkinsonism.
    Vintonyak O; Gorges M; Müller HP; Pinkhardt EH; Ludolph AC; Huppertz HJ; Kassubek J
    Neurodegener Dis; 2017; 17(4-5):117-126. PubMed ID: 28268209
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Brain alpha-synuclein accumulation in multiple system atrophy, Parkinson's disease and progressive supranuclear palsy: a comparative investigation.
    Tong J; Wong H; Guttman M; Ang LC; Forno LS; Shimadzu M; Rajput AH; Muenter MD; Kish SJ; Hornykiewicz O; Furukawa Y
    Brain; 2010 Jan; 133(Pt 1):172-88. PubMed ID: 19903734
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cortical thickness, surface area and volume measures in Parkinson's disease, multiple system atrophy and progressive supranuclear palsy.
    Worker A; Blain C; Jarosz J; Chaudhuri KR; Barker GJ; Williams SC; Brown R; Leigh PN; Simmons A
    PLoS One; 2014; 9(12):e114167. PubMed ID: 25463618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The contribution of cerebellar proton magnetic resonance spectroscopy in the differential diagnosis among parkinsonian syndromes.
    Zanigni S; Testa C; Calandra-Buonaura G; Sambati L; Guarino M; Gabellini A; Evangelisti S; Cortelli P; Lodi R; Tonon C
    Parkinsonism Relat Disord; 2015 Aug; 21(8):929-37. PubMed ID: 26077167
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantitative metabolomics of saliva using proton NMR spectroscopy in patients with Parkinson's disease and healthy controls.
    Kumari S; Goyal V; Kumaran SS; Dwivedi SN; Srivastava A; Jagannathan NR
    Neurol Sci; 2020 May; 41(5):1201-1210. PubMed ID: 31897951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.